Go to Page # Page of 48

Developing Breakthrough Therapies in Nash & Mucopolysaccharidosis

 Frédéric Cren, Pierre Broqua PhD, Jean Volatier, Marie-Paule Richard MD
Description: Inventiva investment highlights for clinical stage biotech with a focus on oral small molecules for high unmet need in fibrosis, lysosomal storage disorders and oncology.
Views: 702
Domain: Medical
Category: Biotech/Pharma
Contributing Organization: Inventiva
 ‐ More of their Presentations
Developing breakthrough therapies in
NASH and mucopolysaccharidosis
Corporate Presentation
April 2019

This document has been prepared by Inventiva (the "Company") solely for the purpose of this presentation. This presentation includes only summary information and does not purport to be
comprehensive. Any information in this presentation, whether from internal or from external sources, ... See more

Recent Presentations

Tine Peeters
21 July, 2019

FDA's Approach to the Opioids Crisis

FDA is working in a prioritized way in multiple areas to confront opioid overdoses while working to ensure patients receive appropriate pain treatment.

20 July, 2019
19 July, 2019